Shamsi, Kohkan <br/><br/>
A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data.  [electronic resource] 

 -  Investigative radiology  Nov 2006 
 - 822-30 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0020-9996 
<br/><br/><label>Standard No.: </label>10.1097/01.rli.0000242836.25299.8f  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Blood Chemical Analysis<br/>Dose-Response Relationship, Drug<br/>Gadolinium--administration & dosage<br/>Humans<br/>Injections<br/>Magnetic Resonance Angiography<br/>Middle Aged<br/>Organometallic Compounds--administration & dosage<br/>Peripheral Vascular Diseases--blood<br/>Urinalysis